Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiotherapy and Weekly Chemo for Stage III NSCLC
NCT03900117Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2019
- Primary completion
- Jun 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel and nedaplatin in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 3 years. Started Mar 2019; status: completed.
02
Drugs
docetaxelnedaplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03900117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900117.